Content area

|
|

Kardiovaskulære risici ved behandling med nonsteroide antiinflammatoriske lægemidler

Forfatter(e)
Morten Schmidt1, 2, Emil Loldrup Fosbøl3, Christian Torp-Pedersen4, 5, Anne-Marie Schjerning Olsen6, Bo Christensen7 & Gunnar H. Gislason6, 8 1) Klinisk Epidemiologisk Afdeling, Aarhus Universitetshospital 2) Medicinsk Afdeling, Regionshospitalet Randers 3) Kardiologisk Afdeling, Rigshospitalet 4) Institut for Medicin og Sundhedsteknologi, Aalborg Universitet 5) Kardiologisk Afdeling, Aalborg Universitetshospital 6) Hjertemedicinsk Afdeling, Herlev og Gentofte Hospital 7) Sektion for Almen Medicin, Institut for Folkesundhed, Aarhus Universitet 8) Forskningsafdelingen, Hjerteforeningen Ugeskr Læger 2016;178:V08160612
Reference: 
Ugeskr Læger 2016;178:V08160612
Blad nummer: 
Sidetal: 
2-6
Cardiovascular risks of non-steroidal anti-inflammatory drugs treatment
Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs. Current evidence supports that all NSAIDs increase the risk of heart failure and elevate blood pressure, whereas the risk of thrombotic events varies with the type of drug. Use of newer selective cyclooxygenase-2 inhibitors has been associated with a substantial vascular risk but increasing concern also relates to traditional NSAIDs, in particular diclofenac. This review summarizes the current evidence regarding the cardio­vascular safety of NSAIDs and presents recommendations for their use.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Gert Einar Storm Kristensen | 20/11
1 Kommentar
af Finn Olav Hansen | 20/11
10 kommentarer
af Svend Erik Gundestrup | 19/11
12 kommentarer
af Anders Mark Christensen | 19/11
1 Kommentar
af Jens Meyer Svendsen | 17/11
1 Kommentar
af Peter Søndergaard | 17/11
1 Kommentar
af Tom Nygaard Kristensen | 16/11
1 Kommentar
af Susanne Udengaard Gydesen | 16/11
6 kommentarer
af Lars Otto Hutters | 16/11
2 kommentarer